The clinical response rates to immune checkpoint inhibitors (anti-PD-1/PD-L1) range restricted 10–30% [47], mostly because of the complex tumor micro environment and immune reconstitution mechanisms employed by cancer cells [48]. This evidence concerns the gene CD274 and neoplasm.